Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Issue 23 (10th September 2013)

• Record Type: Journal Article
• Authors: Okuwaki, Kosuke; Kida, Mitsuhiro; Mikami, Tetuo; Yamauchi, Hiroshi; Imaizumi, Hiroshi; Miyazawa, Shiro; Iwai, Tomohisa; Takezawa, Miyoko; Saegusa, Makoto; Watanabe, Masahiko; Koizumi, Wasaburo
• Is Part Of: Cancer. Volume 119:Issue 23(2013)
• Page Start: 4094
• Page End: 4102
• Publication Date: 2013-09-10
• Subjects: pancreatic neuroendocrine tumors -- neuroendocrine tumor -- somatostatin receptor type 2A -- SSTR‐2a -- 2010 World Health Organization classification; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28341
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: The impact of somatostatin receptor type 2 (SSTR‐2a) expression levels on outcomes in patients with pancreatic neuroendocrine tumors (PNETs) has not been evaluated. METHODS: Correlations between clinicopathologic characteristics, including SSTR‐2a expression and outcomes, were retrospectively studied in 79 patients with pancreatic neuroendocrine tumors (PNETs). RESULTS: The SSTR‐2a score was 0 in 27% of patients, 1 in 24% of patients, 3 in 30% of patients, and 4 in 18% of patients. The overall survival rate was 87% at 1 year, 77% at 3 years, and 71% at 5 years. On univariate analysis, a pancreatic tumor that measured ≥20 mm in greatest dimension, stage IV disease, vascular invasion, neuroendocrine carcinoma (NEC), and an SSTR‐2a score of 0 were associated significantly with poor outcomes. On multivariate analysis, NEC ( P = .000; hazard ratio, 28.8; 95% confidence interval, 7.502‐111.240) and an SSTR‐2a score of 0 ( P = .001; hazard ratio, 3.611; 95% confidence interval, 1.344‐9.702) were related independently to poor outcomes. CONCLUSIONS: The current analysis of prognostic factors in patients with PNETs demonstrated that NEC and an SSTR‐2a score of 0 both were significant independent predictors of poor outcomes. The results suggest that the assessment of SSTR‐2a may facilitate the selection of treatment regimens and the prediction of outcomes. Because a considerable proportion of patients with NEC have SSTR‐2a‐positive tumors, further analyses of the usefulness of somatostatin analogues are warranted in patients who have SSTR‐2a‐positive NEC. Cancer 2013. © 2013 American Cancer Society. Abstract : In an analysis of prognostic factors among patients with pancreatic neuroendocrine tumors, a somatostatin receptor type 2A score of 0 is a significant independent predictor of poor outcomes. The assessment of somatostatin receptor type 2A may facilitate the selection of treatment regimens and the prediction of outcomes.